[Functions and Indications]
Tongxinluo Capsules is a representative drug for the treatment of cardiovascular and cerebrovascular diseases guided by the innovation of collateral disease theory. It can effectively prevent the occurrence of arteriosclerosis by its exact lipid-lowering, anti-inflammatory, anticoagulant and vascular endothelial protection, and is suitable for the prevention of hypertension, hyperlipidemia, hyperglycemia and obesity. By virtue of its effect of relieving vasospasm and reversing and stabilizing plaques, it can be used in the treatment of atherosclerotic plaques and reduce the occurrence of myocardial infarction and cerebral infarction caused by plaque rupture. It can protect capillaries, improve the blood flow perfusion for microcirculation, solve the worldwide problems of microvascular protection, and has definite curative effect on the treatment and prevention of the recurrence of acute myocardial infarction and cerebral infarction and also diabetic microvascular complications.

[Main Ingredients] Ginseng Radix et Rhizoma, Hirudo, Scorpio, Paeoniae Rubra Radix, Periostracum Cicadae, Eupolyphaga seu Steleophaga, Scolopendra, Lignum Santali Albi, Lignum Dalbergiae Odoriferae, Oblibanum (processed), Ziziphi Spinosae Semen (stirbaked), Borneolum Syntheticum.

[Dosage] Take orally, 2 to 4 capsules/time, 3 times/day, 4 weeks for a course of treatment.

[Specification] 0.26g/capsule.

[Packing] Blister package, 30 capsules/box, 400boxes/carton.

[MA Number] License of State Drug Administration Z19980015.

● National Essential Drug List
● National Class- A Varieties for Medical Insurance Drugs
● National Key New Product
● Essential TCM medicines for Emergency Treatment in TCM Hospitals
● Confidential Varieties and High-tech Product Designated by the Ministry of Science and Technology of the P.R.C.

Major theoretical research on original prescriptions: “Research on Tongxinluo Capsules in the Treatment of Coronary Heart Disease” won the Second Prize for National Progress in Science and Technology in 2000.
Research on Collateral Disease Theory and its application: “Research on Collateral Disease Theory and its Application” won the Second Prize for National Progress in Science and Technology in 2006.
Modern superfine comminution pharmaceutical technology: “Superfine Powder Techniques for Insect Medicine and Their Application” won the Second Prize for National Technological Invention in 2007.